Somewhat Positive Media Coverage Somewhat Unlikely to Affect Immune Pharmaceuticals (IMNP) Share Price

Media stories about Immune Pharmaceuticals (NASDAQ:IMNP) have been trending somewhat positive on Thursday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.476175915692 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

NASDAQ IMNP traded down $0.01 during midday trading on Thursday, hitting $0.23. The company had a trading volume of 2,255,888 shares, compared to its average volume of 1,116,044. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.15. Immune Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $3.43.

Immune Pharmaceuticals (NASDAQ:IMNP) last announced its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.

IMNP has been the subject of several research reports. Maxim Group set a $2.00 price target on Immune Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, April 3rd. ValuEngine raised Immune Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases.

Insider Buying and Selling by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply